http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001525802-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 1998-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001525802-A |
| titleOfInvention | Substituted 1,2,4-triazolo [3,4-a] phthalazine derivatives as GABAα5 ligands |
| abstract | (57) [Summary] A compound of the following formula (I) wherein R 1 is hydrogen, halogen or CN or CF 3 group, OCF 3 group, C 1-4 alkyl group, C 2-4 alkenyl group, C 2 A 2-4 alkynyl group, a C 1-4 alkoxy group, a C 2-4 alkenyloxy group or a C 2-4 alkynyloxy group; each of which is unsubstituted or has one or two halogen atoms; Each of which is unsubstituted or independently substituted by one or two halogen atoms or nitro, cyano, amino, methyl or CF 3 atoms or pyridyl or phenyl rings; R 2 is hydrogen, halogen or CN or CF 3 , OCF 3 , C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1 -4 alkoxy, C 2-4 alkenyloxy group Properly is an C 2-4 alkynyloxy group; each of which groups or an end substituted with one or is substituted with two halogen atoms; L is, O, S or NR n; R n is H, C 1-6 alkyl or C 3-6 cycloalkyl; X is a 5- or 6-membered optionally substituted heterocycle; Y is an oxo group-substituted Or a branched C 1-4 alkylidene, or Y is a (CH 2 ) j O group (the oxygen atom is adjacent to the X group, and j is 2, 3 or 4 Z) is a 5- or 6-membered optionally substituted heterocycle]; or a pharmaceutically acceptable salt of the compound; a pharmaceutical composition comprising the compound, that in medical treatment Are disclosed, methods of making the compounds, and intermediates used in the methods. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009081970-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7351590-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8410277-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8507530-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8513287-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8153662-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8158657-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2009081970-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8841327-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8188119-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8183264-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11220503-B2 |
| priorityDate | 1997-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.